Chimerix (NASDAQ:CMRX – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Tuesday, August 13th. Analysts expect Chimerix to post earnings of ($0.23) per share for the quarter.
Chimerix Stock Performance
Chimerix stock opened at $0.84 on Wednesday. The company’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $0.98. Chimerix has a 1 year low of $0.78 and a 1 year high of $1.30. The company has a market capitalization of $75.58 million, a price-to-earnings ratio of -0.91 and a beta of 1.20.
Analyst Ratings Changes
Separately, StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research note on Saturday, June 8th.
About Chimerix
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
- Five stocks we like better than Chimerix
- What is the Australian Securities Exchange (ASX)
- Lumen’s Q2: Can AI Revenue Outshine a Mountain of Debt?
- What is a Stock Market Index and How Do You Use Them?
- Carry Trade Ending: Recent Market Turbulence and Future Risks
- What is the Dogs of the Dow Strategy? Overview and Examples
- Stocks Slide: Trillions Lost, More Downside Ahead?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.
